Page 45 - Binder2

structural irregularities that can trigger antibody
formation.
• Tolerogenic delivery platforms—from
nanoparticles to mucosal adjuvants—that condition
the immune system to recognize therapeutic
proteins as safe, reinforcing regulatory T-cell
activity rather than provoking immune attack.

These are not science fiction. They are in development.
Some are in clinical trials. A few are nearing approval.
They are real, testable, and increasingly scalable.

From Expensive Fixes to Durable Solutions

For too long, we’ve treated tolerization with the
aforementioned reactive patches—dose escalation,
immunosuppressants, switching drugs, layering therapies.
Each step adds cost, complexity, and cumulative risk. Each
step is a detour around the real problem.

But a new model is emerging. One where the value of a
biologic isn’t just measured in initial response rates, but
in long-term immune stability. Where success means
staying on one therapy for years—not bouncing
between expensive disappointments. Where biologics
become not just potent, but trusted. Predictable. Durable.

In this model, cost curves flatten. Patient outcomes
stabilize. And biologics finally deliver on their original
promise—not as high-risk gambles, but as reliable
platforms for chronic disease management.

This is the solution the industry never made time for. Now
it must.

43